Approval · Notice of Compliance 28601 · 2022
MAR-RIZATRIPTAN: Notice of Compliance 28601
Issued July 14, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28601
- Date
- July 14, 2022
- Company
- Marcan Pharmaceuticals Inc.Ottawa, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph, Package Insert and Labelling
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAR-RIZATRIPTAN | Not yet assigned | — |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB